FederalCircuit Reverses District Court's Invalidity Ruling on Written Description in Novartis v. Torrent February 18, 2025 In a precedential opinion issued on January 10, 2025, the United States Court ...
NHK-Fintiv Rule Challenges Look Futile at FederalCircuit April 6, 2021 The NHK-Fintiv rule allows the Patent Trial and Appeal Board (PTAB) to deny institution of an inter partes review petition based ...
On June 30, the U.S. Court of Appeals for the FederalCircuit (CAFC) issued a precedential decision regarding transitional phrase claim construction, reversing the decision of the Patent Trial and Appeal ...
FederalCircuit Remands to PTAB to Further Consider Pfizer's Motion to Amend Claims March 13, 2024 In a recent ruling regarding Pfizer's pneumococcal vaccine patent (U.S. Patent No. 9,492,559), the ...
The FederalCircuit Takes Design Patent Obviousness En Banc July 11, 2023 The FederalCircuit on June 30 granted a petition for re-hearing en banc of its per curiam decision in LKQ Corp. v. GM Global ...
Supreme Court Affirms FederalCircuit Decision in Amgen v. Sanofi May 18, 2023 In a unanimous opinion the Court decided that the FederalCircuit’s decision was correct. The Court noted that that ...
FederalCircuit Upholds PTAB Finding of Patentability in Medtronic v. Teleflex Life Sciences April 1, 2024 In Medtronic, Inc. v. Teleflex Life Sciences Ltd. the FederalCircuit upheld the Patent Trial ...
FederalCircuit Reiterates: Isolated Natural Products Alone Are Not Patent Eligible Without A Markedly Different Characteristic March 3, 2023 co-authored by Sara Pistilli, PharmD. and Richard D. Kelly ...
FederalCircuit Upholds PTAB Finding of Obviousness in Pfizer vs. Sanofi March 18, 2024 In Pfizer Inc. vs. Sanofi Pasteur Inc., the FederalCircuit upheld the Patent Trial and Appeal Board (PTAB) decision ...
FederalCircuit Upholds Invalidity Based on Mandatory Publication of Clinical Trial Protocol May 16, 2024 Clinical trials are a critical part of the development and approval process for drugs, biologics,...